Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

53.45USD
22 Aug 2014
Price Change (% chg)

$-0.16 (-0.30%)
Prev Close
$53.61
Open
$53.61
Day's High
$53.99
Day's Low
$53.35
Volume
318,897
Avg. Vol
577,388
52-wk High
$55.70
52-wk Low
$36.26

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.65
Market Cap (Mil.): $51,336.00
Shares Outstanding (Mil.): 952.04
Dividend: 0.35
Yield (%): 2.56

Financials

  TEVA.N Industry Sector
P/E (TTM): 17.66 33.74 34.44
EPS (TTM): 3.04 -- --
ROI: 7.47 18.86 18.11
ROE: 11.47 19.48 18.84
Search Stocks

BRIEF-Active Biotech's partner Teva initiates trial in Huntington's disease

Aug 14 - Active Biotech : * Active biotech's partner teva initiates a laquinimod clinical trial in

14 Aug 2014

UPDATE 1-Teva Pharm raises full-year profit forecast after solid second quarter

* Now sees 2014 EPS $4.50-$4.80 with Copaxone competition

31 Jul 2014

Teva Pharm shareholder optimistic of change despite losing vote

JERUSALEM, July 31 - Israeli industrialist Benny Landa said his campaign to improve corporate governance at Teva Pharmaceutical Industries was delivering results, despite losing a shareholder vote at the world's largest generic drugmaker.

31 Jul 2014

BRIEF-Teva 2014 revenue outlook

July 31 - Teva Pharmaceutical Industries Ltd said:

31 Jul 2014

Teva Pharm Q2 profit, revenue up on generic launches

TEL AVIV, July 31 - Teva Pharmaceutical Industries reported on Thursday higher quarterly earnings that beat analysts' estimates by one cent due in part to the launch of several generic products in the United States.

31 Jul 2014

Teva says shareholders favor management as shakeup fizzles

July 30 - Israeli drugmaker Teva Pharmaceuticals Industries said on Wednesday it turned back efforts by Israeli industrialist Benny Landa to shake up the company's board of directors, with shareholders approving all of the company's proposals and board nominations.

31 Jul 2014

Teva to name new chairman - activist investor Landa says

TEL AVIV, July 14 - Teva Pharmaceutical Industries board is to appoint vice-chairman Amir Elstein as its new chairman, activist shareholder Benny Landa said on Monday.

14 Jul 2014

UPDATE 2-EU fines 6 drug firms 428 mln euros for blocking cheaper drugs

* Six companies get combined penalty of 428 million euros

09 Jul 2014

EU regulators fine Servier, Teva, others 428 mln euros

BRUSSELS, July 9 - European Union antitrust regulators fined French drugmaker Servier, Israel's Teva and four others 427.7 million euros ($583.40 million) on Wednesday for blocking cheaper generic medicine.

09 Jul 2014

Teva files petition with U.S. FDA against MS drug competitors

TEL AVIV, July 3 - Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration (FDA), aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis (MS).

03 Jul 2014

Competitors

  Price Change
Novartis AG (NOVN.VX) CHF81.35 +0.25
Biogen Idec Inc (BIIB.OQ) $339.97 +1.32

Earnings vs. Estimates

Search Stocks